Prostate cancer drug shows 58% reduction in relapse for high-risk patients in Australian-led trial
Darolutamide added to standard therapy dramatically cuts spread of aggressive disease, researchers say
A major Australian-led global trial has found that adding the hormone-blocking drug darolutamide to standard treatment reduces the risk of relapse by 58% in men with very high-risk prostate cancer, prompting calls to change the standard of care for this group. The findings, involving 1106 participants, were due to be announced at the European Society of Medical Oncology Congress in Madrid.